Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation.
about
The Immunology of Posttransplant CMV Infection: Potential Effect of CMV Immunoglobulins on Distinct Components of the Immune Response to CMVTwelve-month efficacy and safety of the conversion to everolimus in maintenance heart transplant recipientsAging is not programmed: genetic pseudo-program is a shadow of developmental growth.Potential of protein kinase inhibitors for treating herpesvirus-associated disease.Everolimus in heart transplantation: an update.Emerging cytomegalovirus management strategies after solid organ transplantation: challenges and opportunities.Chronic renal insufficiency in heart transplant recipients: risk factors and management options.Cytomegalovirus Immunoglobulin After Thoracic Transplantation: An OverviewSafety of mTOR inhibitors in adult solid organ transplantation.New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation.Treatment and prevention of cytomegalovirus infection in heart and lung transplantation: an update.Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients.mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid.The CECARI Study: Everolimus (Certican®) Initiation and Calcineurin Inhibitor Withdrawal in Maintenance Heart Transplant Recipients with Renal Insufficiency: A Multicenter, Randomized Trial.Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies.Optimizing the Safety Profile of Everolimus by Delayed Initiation in De Novo Heart Transplant Recipients: Results of the Prospective Randomized Study EVERHEART.Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial.The Past, Present and Future of Heart Transplantation.
P2860
Q26768481-EF6A3A67-98B4-44C0-8B3F-FB183D7E1D4CQ36400864-88608C98-8F84-4654-BD0F-8A19FB721681Q37525814-631A3376-33D0-40E9-AD93-F951D3DD0869Q38100859-AF31EC78-0ACD-4FCE-9957-D36D6062E1E9Q38175144-5EA35AA2-2B99-44BB-AE3B-12ECA6CCCCDCQ38225475-A2FCE110-AA78-42D4-9DB2-C2532E41DCDEQ38240994-633CCDFE-F443-4FF5-9EEB-0BCB280AF69DQ38599972-D869DEB2-7821-429E-9757-3A6C9F3BBEF1Q38669190-85179D6E-DF69-4004-8A84-5376D9CA6DA3Q38711763-209BF72D-0884-4EE0-83CE-E7908D286040Q38875887-7DB9D82C-5D76-4FA2-917E-74334BA78700Q38947867-948C2CFB-664F-4B82-BD68-125AFE6E83CAQ38962103-3208DB66-0BFE-417B-B74F-40AF62D1A38EQ40856064-DFEDCE38-5546-4E91-93AD-5EE4FEE6FC1FQ41847223-6FC540CB-1901-433A-813F-19548997E0DCQ43280688-6F80F17A-6F1E-4B99-A0BD-AB35844E1CB7Q49990142-BCE264F0-9AE7-489A-B1DA-BD1A5DB59F5DQ51067478-59CBAAAD-ED42-40A9-8A58-B7ABEB121B10Q55437542-828E898F-C4A8-466F-BBE1-B1C04D2B0B26
P2860
Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Everolimus is associated with ...... novo cardiac transplantation.
@en
Everolimus is associated with ...... novo cardiac transplantation.
@nl
type
label
Everolimus is associated with ...... novo cardiac transplantation.
@en
Everolimus is associated with ...... novo cardiac transplantation.
@nl
prefLabel
Everolimus is associated with ...... novo cardiac transplantation.
@en
Everolimus is associated with ...... novo cardiac transplantation.
@nl
P2093
P2860
P50
P356
P1476
Everolimus is associated with ...... e novo cardiac transplantation
@en
P2093
H B Lehmkuhl
P2860
P304
P356
10.1111/TID.12007
P577
2012-09-26T00:00:00Z